Single Blog

Introduction: From Inhibitors to “Molecular Assassins”

For decades, small molecule drugs have worked like chemical “brakes,” inhibiting enzymes or receptors to dial down disease-driving pathways. A new wave of molecules is changing that paradigm. Targeted protein degraders, especially PROTACs (PROteolysis TArgeting Chimeras), act more like “molecular assassins”: they mark harmful proteins for destruction by the cell’s own waste-disposal system, the proteasome. This event-driven mechanism is redefining what we consider druggable and how we think about durability, selectivity, and resistance in pharmacology
doi:10.1038/nrd.2017.152.

What Exactly Are PROTACs?

PROTACs are bifunctional small molecules with three key components:

• Target-binding ligand: Recognizes and binds the disease-relevant protein.
• E3 ligase ligand: Recruits an E3 ubiquitin ligase such as cereblon (CRBN) or von Hippel–Lindau (VHL).
• Linker: Connects the two ligands and positions them to form a productive ternary complex.

Once the PROTAC bridges the target protein and the E3 ligase, the target is tagged with ubiquitin and subsequently degraded by the proteasome. Crucially, a single PROTAC molecule can catalytically trigger degradation of multiple target proteins and then “walk away,” enabling potent effects at relatively low exposures
doi:10.1038/nrd.2017.152.

Why PROTACs Are a Game Changer

1. Expanding the Druggable Proteome

Traditional inhibitors require a well-defined active site, which many proteins simply do not have. PROTACs only need a binding surface, not an enzymatic pocket, allowing access to:

• Transcription factors and scaffolding proteins
• Epigenetic regulators such as BET family proteins
• Mutant kinases that evade conventional inhibitors

Early studies showed that BET-targeting PROTACs can efficiently degrade BRD4 and suppress oncogenic transcription programs that are difficult to modulate with classic inhibitors
doi:10.1038/nchembio.2263.

2. Hitting Both Catalytic and Non-Catalytic Functions

Many signaling proteins act as scaffolds, organizing complexes even when their catalytic site is blocked. By removing the entire protein, PROTACs eliminate both enzymatic and structural roles, often resulting in deeper pathway shutdown than inhibition alone
doi:10.1038/nchembio.2263.

3. A New Strategy Against Drug Resistance

Resistance to small molecule inhibitors frequently arises through:

• Point mutations that reduce drug binding
• Overexpression of the target protein
• Compensatory signaling via non-catalytic functions

PROTACs can degrade mutant variants, reduce total protein levels, and disable scaffolding functions. PROTACs directed at BTK and BCR-ABL have shown activity against clinically relevant resistance mutations in preclinical models
doi:10.1021/acsmedchemlett.8b00052.

Design Principles: What Makes a PROTAC Work?

1. Choosing the Right Target and E3 Ligase Ligands

The identity of the E3 ligase is not a trivial detail; it shapes tissue selectivity and safety. CRBN and VHL are the most widely used, but their expression patterns differ across cell types, influencing:

• Where degradation occurs (tumor vs. normal tissue)
• Potential off-target effects
• Combination strategies with existing therapies

Rational pairing of target ligands with specific E3 ligase ligands, informed by transcriptomics and proteomics, is becoming a core design strategy
doi:10.1016/j.cell.2019.01.033.

2. Linker Engineering: Small Changes, Big Consequences

The linker governs the geometry of the ternary complex. Minor tweaks in:

• Length (short vs. extended)
• Flexibility (rigid aromatic vs. flexible alkyl)
• Polarity (PEG-based vs. hydrophobic)

can flip a PROTAC from non-functional to highly potent. Structure–activity relationship (SAR) campaigns now routinely explore “linker space” using computational modeling and, increasingly, AI-driven conformational analysis
doi:10.1038/nrd.2017.152.

From Bench to Bedside: PROTACs in the Clinic

The first wave of clinical PROTACs is focused on hormone-driven cancers:

• ARV-110 (bavdegalutamide): An androgen receptor degrader for metastatic castration-resistant prostate cancer. Early trials show target degradation, PSA declines, and activity in patients previously treated with next-generation AR inhibitors
  doi:10.1158/2159-8290.CD-20-1793.
• ARV-471 (vepdegestrant): An estrogen receptor degrader for ER-positive breast cancer, demonstrating robust ER degradation and promising clinical responses, including in endocrine-resistant disease
  doi:10.1038/s41591-021-01664-3.

These data provide proof-of-concept that orally available small molecule degraders can be safe, pharmacokinetically tractable, and clinically active.

Beyond Oncology: Where PROTACs Are Headed Next

The same degradation logic can be applied far beyond cancer:

• Neurodegeneration: Selective degradation of tau, α-synuclein, or huntingtin could enable truly disease-modifying approaches in Alzheimer’s, Parkinson’s, and Huntington’s disease.
• Immunology: Temporally controlled degradation of signaling nodes in T cells or innate immune cells may allow precise immune tuning rather than blanket suppression.
• Virology: Degrading viral proteins or host factors essential for viral replication is emerging as a novel antiviral strategy
  doi:10.1016/j.drudis.2020.02.007.

Key challenges include oral bioavailability for large, polar molecules, minimizing off-target degradation, and achieving brain or tissue-specific delivery—but rapid advances in medicinal chemistry, AI-guided design, and high-throughput proteomics are closing these gaps.

Conclusion: A New Pillar of Small Molecule Drug Discovery

Targeted protein degraders are transforming small molecule therapeutics from reversible inhibitors into programmable, catalytic destroyers of disease-driving proteins. By accessing previously “undruggable” targets, overcoming resistance, and offering pathway-level control, PROTACs are poised to become a foundational modality alongside antibodies, RNA therapeutics, and classic small molecules. As clinical data mature and design tools improve, the question is no longer if protein degradation will reshape drug discovery—but how quickly it will redefine the standard of care across oncology, neurology, immunology, and beyond
doi:10.1038/nrd.2017.152,
doi:10.1038/nchembio.2263,
doi:10.1038/s41591-021-01664-3,
doi:10.1016/j.drudis.2020.02.007.